01 January 2001
NCX4016 (NO-aspirin) inhibits thromboxane biosynthesis and tissue factor expressionand activity in human monocytes.
Pietro Minuz, Maurizio Degan, Stefania Gaino, Alessandra Meneguzzi, Valeria Zuliani, Clara Lechi Santonastaso, Piero Del Soldato, Alessandro LechiMed Sci Monit 2001; 7(4): BR573-577 :: ID: 421101
Abstract
BACKGROUND: NCX4016 (2 acetoxy-benzoate 2-(2-nitroxymethyl)-phenyl ester,NicOx S.A., France) is an antithrombotic agent chemically related to acetylsalicylic acid (ASA). We hypothesisedthat NCX4016, being able to release nitric oxide (NO) and to inhibit cyclo-oxygenase, might inhibit theprothrombotic function in human monocytes.MATERIAL AND METHODS: The effects of NCX4016 and ASA on therelease of thromboxane (TX) B2 and tissue factor expression and activity were compared using adherenthuman monocytes. The tested drugs were added before stimulation with 10 Kg/ml LPS and incubation lasted6 hours. TXB2 concentration was measured by RIA in the supernatant of cultured cells. Immunoreactivetissue factor (TF) concentration was determined by enzyme-linked immunoassay and TF activity was assayedby measuring the peptidyl activity of the tissue factor/ factor VII complex.RESULTS: Both ASA and NCX401610-300 Kmol/L dose-dependently reduced TXB2 release. NCX4016 activity was comparable to that of equimolarASA. Part of the activity of NCX4016 up to 100 Kmol/L was prevented by 10 Kml/L ODQ, inhibitor of cGMPgeneration. Immunoreactive TF was dose-dependently inhibited by 300 Kmol/L NCX4016, but not by ASA. Alsotissue TF activity was reduced by 300 Kmol/L NCX4016, but not by ASA.CONCLUSIONS: The present resultsindicate that NCX4016 not only has anti-platelet effects but also inhibits prothrombotic activities inhuman monocytes, partly via NO-dependent mechanisms. NCX4016 may prove effective in the clinical settingof athero-thrombosis.
Keywords: Aspirin, Monocytes, Nitric Oxide Donors, Nitroso Compounds, Platelet Aggregation Inhibitors, Thromboplastin, Thromboxane B2
Editorial
01 March 2024 : Editorial
Editorial: First Regulatory Approvals for CRISPR-Cas9 Therapeutic Gene Editing for Sickle Cell Disease and Transfusion-Dependent β-ThalassemiaDOI: 10.12659/MSM.944204
Med Sci Monit 2024; 30:e944204
In Press
18 Mar 2024 : Clinical Research
Sexual Dysfunction in Women After Tibial Fracture: A Retrospective Comparative StudyMed Sci Monit In Press; DOI: 10.12659/MSM.944136
21 Feb 2024 : Clinical Research
Potential Value of HSP90α in Prognosis of Triple-Negative Breast CancerMed Sci Monit In Press; DOI: 10.12659/MSM.943049
22 Feb 2024 : Review article
Differentiation of Native Vertebral Osteomyelitis: A Comprehensive Review of Imaging Techniques and Future ...Med Sci Monit In Press; DOI: 10.12659/MSM.943168
23 Feb 2024 : Clinical Research
A Study of 60 Patients with Low Back Pain to Compare Outcomes Following Magnetotherapy, Ultrasound, Laser, ...Med Sci Monit In Press; DOI: 10.12659/MSM.943732
Most Viewed Current Articles
16 May 2023 : Clinical Research
Electrophysiological Testing for an Auditory Processing Disorder and Reading Performance in 54 School Stude...DOI :10.12659/MSM.940387
Med Sci Monit 2023; 29:e940387
17 Jan 2024 : Review article
Vaccination Guidelines for Pregnant Women: Addressing COVID-19 and the Omicron VariantDOI :10.12659/MSM.942799
Med Sci Monit 2024; 30:e942799
14 Dec 2022 : Clinical Research
Prevalence and Variability of Allergen-Specific Immunoglobulin E in Patients with Elevated Tryptase LevelsDOI :10.12659/MSM.937990
Med Sci Monit 2022; 28:e937990
01 Jan 2022 : Editorial
Editorial: Current Status of Oral Antiviral Drug Treatments for SARS-CoV-2 Infection in Non-Hospitalized Pa...DOI :10.12659/MSM.935952
Med Sci Monit 2022; 28:e935952